[go: up one dir, main page]

WO1997041832A1 - Suspension de medicament acide difficilement soluble dans l'eau - Google Patents

Suspension de medicament acide difficilement soluble dans l'eau Download PDF

Info

Publication number
WO1997041832A1
WO1997041832A1 PCT/JP1997/001496 JP9701496W WO9741832A1 WO 1997041832 A1 WO1997041832 A1 WO 1997041832A1 JP 9701496 W JP9701496 W JP 9701496W WO 9741832 A1 WO9741832 A1 WO 9741832A1
Authority
WO
WIPO (PCT)
Prior art keywords
water
soluble
suspension
ibuprofen
average particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1997/001496
Other languages
English (en)
Japanese (ja)
Inventor
Mayumi Naito
Hiroshi Nakano
Kazuo Hasegawa
Toshiaki Nakajima
Ichiro Okudaira
Kenji Tsunoda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Priority to EP97918348A priority Critical patent/EP0896815A4/fr
Priority to US09/171,631 priority patent/US6231890B1/en
Priority to AU26503/97A priority patent/AU717764B2/en
Publication of WO1997041832A1 publication Critical patent/WO1997041832A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Definitions

  • the present invention relates to a composition in which a poorly water-soluble acidic drug (and inorganic powder) is suspended in fine particles, and a method for producing the same.
  • a liquid preparation of a drug having an analgesic activity and an anti-inflammatory activity such as a poorly water-soluble acidic drug, for example, a non-steroid drug
  • a suspension type syrup disclosed in No. 5, but there is a problem in stability of suspended particles over time. That is, in the suspensions provided so far, it is described that the particle size of ibuprofen is preferably 30 to 250 m, and if it is smaller than this range, it floats, and if it is larger, it sediments and it is not preferable. I have.
  • the suspended solids settled tightly at the bottom of the container and must be re-dispersed by shaking vigorously at the time of ingestion, but this re-dispersion is extremely difficult and re-dispersed. Nevertheless, there was a problem that, when taken, discomfort due to strong graininess occurred, and furthermore, the drug was aggregated in the stomach, failing to exert a sufficient effect.
  • a method of atomizing the drug can be considered.However, with a method using a conventional device such as a homogenizer, the conditions such as the high concentration of the drug and the stabilizer, high viscosity, and low-temperature control are set. It was difficult, and it was difficult to reduce the particle size to the required particle size.
  • An object of the present invention is to provide a water-insoluble acidic drug which is stable over a long period of time and has a high dissolution property, and which can be sterilized at high temperature, reduces irritation to the oropharyngeal mucosa, and has a good It is to provide a turbidity agent.
  • Another object of the present invention is to provide a method for easily and easily producing a suspension having the above excellent properties.
  • the present inventors have conducted intensive studies to improve the dissolution and stability of poorly water-soluble acidic drugs, particularly non-steroid anti-inflammatory analgesics.As a result, the poorly water-soluble acidic drugs having an average particle system of 1 to 15 In the case of a suspension composed of polyglycerin fatty acid ester, water-soluble polyhydric alcohol and water, a poorly water-soluble acidic drug was found to be stable over a long period of time and had a high dissolution property. It has been found that by adding inorganic powder of 1 to 15 m, high-temperature sterilization can be performed and irritation to the oropharyngeal mucosa can be reduced, and the present invention has been completed.
  • the present invention is a suspending agent for a poorly water-soluble acidic drug comprising a poorly water-soluble acidic drug having an average particle diameter of 1 to 15 / zm, a polyglycerin fatty acid ester, a water-soluble polyhydric alcohol and water.
  • a suspension comprising inorganic powder having a diameter of 1 to 15 / xm, polyglycerol fatty acid ester, water-soluble polyhydric alcohol and water, and the present invention further provides a poorly water-soluble acidic drug, polyglycerin fatty acid ester, and water-soluble It consists of a main shaft rotating in a casing, and several sub-shafts that revolve in conjunction with the rotation of the main shaft, and a number of ring-shaped grinding media are attached to each sub-shaft.
  • a method for producing a suspending agent having an average particle diameter of 1 to 15 m of a poorly water-soluble acidic drug which is characterized by being finely pulverized and dispersed by a pulverizer.
  • the poorly water-soluble acidic drug refers to a crystalline compound having a melting point of around 40 to 120, showing crystallinity, being poorly soluble in water in a low pH range, and having an acidic group or a salt thereof, for example.
  • It is essential that the poorly water-soluble acidic drug has an average particle size of 1 to 15 m. If the average particle size is smaller than this range, the stimulation of the poorly water-soluble drug during ingestion becomes strong. If it is too large, the ingestibility and the stability of sedimentation of suspended particles deteriorate.
  • the surfactant must be a polyglycerin fatty acid ester, and polyoxyethylene sorbitan monooleate surfactant (polysorbate 80, etc.) and polyoxyethylene hydrogenated castor oil surfactant (HCO 60, etc.) are ibuprofen. It is not preferable because the solubility is increased and suspended matter is generated with time.
  • polyglycerin fatty acid ester those having a glycerin polymerization degree of 3 or more, a fatty acid having 12 to 22 carbon atoms, a fatty acid having an ester bond of 1 to 7 and a final HLB of 4 or more are preferable.
  • decaglycerin monostearate decaglycerin distearate, heptamine glycerin monostearate, decaglycerin heptinate, and the like are preferred, alone or Two or more kinds can be used as a mixture.
  • the compounding amount of the polyglycerin fatty acid ester is 0.001 to 1.0% by weight, preferably 0.002 to 0.5% by weight in terms of the final preparation. If the amount is less than 0.001% by weight, the dispersibility of the suspended particles is insufficient. If the amount exceeds 1.0% by weight, the solubility of the drug increases, and the irritation increases.
  • water-soluble polyhydric alcohol examples include glycerin, ethylene glycol, propylene glycol, 1,3-butylene glycol, diglycerin, polyglycerin, diethylene glycol, polyethylene glycol, dipropylene glycol, polyethylene glycol, dipropylene glycol, and polypropylene.
  • water-soluble polyhydric alcohols for example, glycerin, diglycerin and polyglycerin are preferred.
  • the blending amount of the water-soluble polyhydric alcohol is 0.01 to 20%, preferably 0.1 to 10%. If it is less than 0.1%, the dispersibility and re-dispersibility of the suspension are poor.
  • Inorganic powders include magnesium component, aluminum component, titanium component, and It is an inorganic compound containing one or more selected from the group consisting of components.
  • examples of such inorganic compounds include magnesium oxide, magnesium hydroxide, magnesium hydroxide alumina, magnesium aluminate metasilicate, magnesium carbonate, magnesium chloride, magnesium sulfate, aluminum oxide, aluminum hydroxide gel, titanium oxide, Light gay anhydride may be used, and these may be used alone or in combination of two or more.
  • Particularly preferred inorganic compounds are titanium oxide, magnesium aluminate hydroxide, aluminum hydroxide gel, and a light or anhydrous silicic acid alone or as a mixture of two or more.
  • the poorly water-soluble acidic drug gives an unacceptably large irritating effect on the oropharyngeal mucosa, but by incorporating the above inorganic powder, the stability of the suspended particles after high-temperature sterilization is improved, and furthermore, It is preferable to add an inorganic powder, since the stimulability of the soluble acidic drug is greatly reduced.
  • the pH of the suspension is preferably 2 to 5, and the suspension of pH 2 to 5 is prepared using a buffer (for example, citrate buffer).
  • a buffer for example, citrate buffer
  • pH is 3-4.
  • a polymer compound not only to improve the sedimentation stability of the suspended particles but also to further improve the stability over time of the suspended particles.
  • a polymer compound examples thereof include xanthan gum, crystalline cellulose, ruboxyl vinyl polymer, ethyl cellulose, hydroxyethyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone, alginic acid, dextrin, sodium hyaluronate, and chondroitin sulfate.
  • These polymer compounds can be used alone or in combination of two or more.
  • polymers having particularly low solubilizing ability such as xanthan gum and crystalline cellulose, are preferred.
  • the ratio of the poorly water-soluble acidic drug (and inorganic powder) to water in the pulverizing step is suitably 5 to 50%, and if it is lower than this range, the pulverizability becomes poor, If it is higher than this range, the viscosity of the pulverized material increases, and pulverization becomes insufficient.
  • Finely pulverized poorly water-soluble acidic drugs (and inorganic powders) exist in a fine form, and the suspended particle size is 15 or less, particularly preferably 1 to 10 is preferred.
  • the suspending agent of the present invention is composed of, for example, a main shaft which mixes each component, and rotates, for example, in a casing, and several sub-shafts which revolve in conjunction with the rotation of the main shaft.
  • the average particle size of the poorly water-soluble acidic drug (and inorganic powder) is adjusted by finely pulverizing it to 1 to 15 m using a pulverizer equipped with a large number of ring-shaped pulverizing media.
  • the milling machine varies depending on the size of the machine and the like.For example, a ring having an outer diameter of 25 to 45 mm and a thickness of several mm is preferable, and a rotation speed of 50 to 500 rpm is preferable. Range.
  • the inorganic powder can be finely pulverized to 1 to 15 separately from the suspending agent and then added to the suspending agent to prepare it.
  • other substances having a protective effect on mucous membranes can be blended.
  • Other mucosal protective substances include sucralfate, other derivatives or calcium salts, mucin, hydroxypropyl methylcellulose, acrylic acid and other natural and Z or synthetic polymer materials.
  • the suspension of the present invention contains other medicinal ingredients such as sodium copper chlorophyllin, azulene, allantoin, aluminum allantinate, silicone oil, funnel extract, Keihi oil, cinnamon oil, other crude drug ingredients, atopin, Gastrointestinal ingredients such as scopolamine and aminoethyl benzoate, vitamins such as vitamins B1, B2, and B6, vitamins C, vitamin A, vitamin D, and vitamin E; calcium preparations such as calcium aspartate and calcium lactate; Other than the above, antipyretic analgesics, muscle relaxants, analgesics, antihistamines, sympathomimetics, and the like can be added as long as the effects of the present invention are not impaired.
  • other medicinal ingredients such as sodium copper chlorophyllin, azulene, allantoin, aluminum allantinate, silicone oil, funnel extract, Keihi oil, cinnamon oil, other crude drug ingredients, atopin, Gastrointestinal ingredients such as scopolamine and aminoethyl benzoate, vitamins such as vitamins B1,
  • substances generally used in pharmaceutical technology such as pharmacologically acceptable sweeteners, pH adjusters, preservatives, flavors, coloring agents and the like can be added.
  • sweetener examples include lactose, sucrose, fructose, glucose, sorbitol, mannitol, erythritol, xylitol, trehalose, stevia extract and the like.
  • pH adjuster examples include lactic acid, citric acid, malic acid, succinic acid, fumaric acid, tartaric acid, phosphoric acid, and salts thereof.
  • preservative examples include parabens such as methyl p-oxybenzoate, ethyl ethyl p-oxybenzoate, propyl p-oxybenzoate, butyl P-oxybenzoate, and benzoic acid or salts thereof.
  • Flavors include orange, grapefruit, apple, lemon, lime, evening sunjeelin, zeus, dwarf orange, nuts, orange, grape, strawberry, pineapple pull, banana, peach, melon, watermelon, plum, cherry, pair, apricot, Fruit-based flavors such as currant, plum, mango, mangosteen, guava, raspberry, blueberry, etc., green tea, tea, cocoa, chocolate, coffee, almond, maple, vanilla, whiskey, brande, lamb, wine, liqueur, cocktail And mint and the like, and these can be used alone or in combination of two or more.
  • Ibuprofen 45 O mg, surfactant 0.05-0.1% by weight, citric acid 100 mg, adjusted to pH 3 with 1N sodium hydroxide, homomixer 800 rotations, 200 After the minute treatment, the ibuprofen particles were sedimented by centrifugation, the supernatant was filtered with a 0.2 m filter, and the concentration of dissolved ibuprofen was determined by HPLC.
  • Ibuprofen 45 Omg, 0.1% by weight of surfactant, lO Omg of citrate, adjusted to pH 3 with 1 N sodium hydroxide, homogen mixer 800 rpm, 20 minutes processing, 65 5 The solution was stored at ° C, 2 °, and 5 and the stability of the ibuprofen suspension was evaluated.
  • polyglycerin fatty acid ester was excellent in stabilizing the suspension over time.
  • the ibuprofen particles were sedimented by centrifugation, the supernatant was filtered through a 0.2 / im filter, and the concentration of dissolved ibuprofen was determined by HPLC.
  • a mixture of 60 g of ibuprofen, 12 g of surfactant (polyglycerol monostearate ester), 50 g of glycerin, and 200 g of 0.5% citrate buffer (pH4) was mixed with Micros MIC-0. (Nara Machinery Co., Ltd.), 100 rpm rotation, 10 minutes, and then diluted 50 times with the above citrate buffer.
  • Micros MIC-0. Nara Machinery Co., Ltd.
  • the amount of ibuprofen, surfactant, and glycerin, diluted 50-fold with citrate buffer was treated with a grinding and dispersing machine as shown in Table 4 (Disperser was used according to the method of Test Example 2, and homomixer was used according to Test Example 1.
  • the particle size was measured using a particle size distribution analyzer (Microtrac).
  • Micros 650 rpm, 10 minutes 3 (1.3-7.3) As shown in Table 4, the particle size of ibuprofen was finely dispersed to 1.3 to 7.3 m by micros treatment, and there was no suspended matter of ibuprofen. Miniaturization was not possible with other equipment. In a dry colloid mill, ibuprofen melted and miniaturization was difficult.
  • a dissolution test was performed using the eluate I solution at 37 ° C. and at 100 rpm according to the paddle method, and ibuprofen was quantified by the HPLC method.
  • Microbubble micronized ibuprofen suspension (average particle size 3 / m) is ibuprofen suspension dispersed in a homomixer. The dissolution rate was remarkably faster than that of the turbidity agent (average particle diameter 36 m).
  • the degree of oil droplets floating on the liquid surface is visually judged, and oily substances are not seen-those that are hardly seen are passed ( ⁇ ), and oily substances that are noticeably seen- Expressed as failed (X).
  • the degree of crystal agglomeration is determined by visually judging the size of the precipitated crystal, and the crystal size is shown as pass ( ⁇ ) when there is no change or almost no change in the size of the crystal. did.
  • citrate buffer pH3
  • Ibuprofen 144 mg Anhydrous caffeine 166 mg Kanzo extract 166 7 mg Geyhi extract 100 mg Shokyo extract 75 mg Polyglycerin monostearate 288 8 mg Glycerin 60 mg Xanthan gum 60 mg Sweetener 10000 mg
  • Ibuprofen 144 mg Anhydrous caffeine 25 mg Dihydrocodine phosphate 8 mg Bromhexine hydrochloride 12 mg Chlorpheniramine maleate 2.5 mgd Methylefedrine hydrochloride 20 mg Lysozyme chloride 30 mg Carrot extract 30 mg Polyglycerin monostearate 2 8.8 mg Glycerin 60 mg Xanthan gum 60 mg Magnesium alumina hydroxide 100 mg Titanium oxide 100 mg
  • the heat stability and dispersion stability of poorly water-soluble acidic drugs are good over a long period of time, the dissolution is high, and the suspended particles are firmly settled on the bottom of the container. It has become possible to provide a suspending agent that does not need to be re-dispersed by vigorous shaking. Further, according to the suspension of the present invention, high-temperature sterilization treatment is possible, and a suspension which does not cause discomfort due to strong graininess when taken can be adjusted.
  • a suspending agent having excellent properties can be produced simply and easily.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une suspension d'un médicament acide difficilement soluble dans l'eau, notamment un analgésique anti-inflammatoire non stéroïdien, qui reste stable longtemps et qui est très facile à dissoudre, ainsi qu'un procédé permettant de produire simplement et facilement ladite suspension. Celle-ci a un pH compris entre 2 et 5, et comprend un médicament acide difficilement soluble dans l'eau, dont le diamètre particulaire moyen est compris entre 1 et 15 νm, un ester d'un polyglycérol d'acide gras, un alcool polyhydrique soluble dans l'eau et de l'eau, ainsi éventuellement qu'une poudre inorganique ayant un diamètre particulaire moyen compris entre 1 et 15 νm. Le procédé est caractérisé par la pulvérisation et la dispersion d'un médicament acide difficilement soluble dans l'eau, d'un ester d'un polyglycérol d'acide gras, d'un alcool polyhydrique et d'eau au moyen d'un pulvérisateur constitué d'un arbre principal conçu pour tourner dans un boîtier et d'une pluralité d'arbres secondaires conçus pour tourner en suivant la rotation de l'arbre principal, chaque arbre secondaire comportant une pluralité de dispositifs de broyage annulaires.
PCT/JP1997/001496 1996-05-02 1997-05-01 Suspension de medicament acide difficilement soluble dans l'eau Ceased WO1997041832A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP97918348A EP0896815A4 (fr) 1996-05-02 1997-05-01 Suspension de medicament acide difficilement soluble dans l'eau
US09/171,631 US6231890B1 (en) 1996-05-02 1997-05-01 Suspension of sparingly water-soluble acidic drug
AU26503/97A AU717764B2 (en) 1996-05-02 1997-05-01 Suspension of sparingly water-soluble acidic drug

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11146896 1996-05-02
JP8/111468 1996-05-02

Publications (1)

Publication Number Publication Date
WO1997041832A1 true WO1997041832A1 (fr) 1997-11-13

Family

ID=14562018

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1997/001496 Ceased WO1997041832A1 (fr) 1996-05-02 1997-05-01 Suspension de medicament acide difficilement soluble dans l'eau

Country Status (7)

Country Link
US (1) US6231890B1 (fr)
EP (1) EP0896815A4 (fr)
KR (1) KR20000010696A (fr)
CN (1) CN1220598A (fr)
AU (1) AU717764B2 (fr)
CA (1) CA2253260A1 (fr)
WO (1) WO1997041832A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005530822A (ja) * 2002-06-17 2005-10-13 ターロ ファーマシューティカルズ ユーエスエイ インコーポレイテッド イブプロフェン懸濁液
JP2006315956A (ja) * 2005-05-10 2006-11-24 Taisho Pharmaceut Co Ltd 解熱鎮痛用固形製剤
JP2006327993A (ja) * 2005-05-26 2006-12-07 Aska Pharmaceutical Co Ltd 鎮痛薬
JP2009513550A (ja) * 2003-07-16 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 慢性侵害受容性疼痛の治療のためのアンブロキソール
JP2009242383A (ja) * 2008-03-10 2009-10-22 Daiichi Sankyo Healthcare Co Ltd イブプロフェン含有安定化内服液
JP2012525359A (ja) * 2009-04-27 2012-10-22 ラボラトリオ デ アプリカシオネス ファルマコディナミカス，エセ．アー． イブプロフェンリシナートの経口投与用の懸濁液

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211246B1 (en) * 1999-06-10 2001-04-03 Mcneil-Ppc, Inc. Rapidly absorbed liquid compositions
US20030170731A1 (en) * 2000-08-02 2003-09-11 Dinan Timothy Garard Diagnosis and treatment of non-ulcer dyspepsia based on hypothalamic-pituitary-adrenal axis abnormallity
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
WO2003026611A2 (fr) * 2001-09-26 2003-04-03 Baxter International Inc. Preparation de nanoparticules submicroniques par dispersion et elimination d'un solvant ou d'une phase liquide
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
ES2197781B1 (es) * 2001-12-04 2005-02-16 Farmalider, S.A. Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno.
DE10203104A1 (de) * 2002-01-25 2003-08-07 Boehringer Ingelheim Pharma Ambroxol für die Behandlung chronischer Schmerzen
DE10208313A1 (de) * 2002-02-27 2003-09-11 Boehringer Ingelheim Pharma Ambroxol für die Behandlung von schmerzhaften Zuständen im Mund und Rachenraum
US20030166732A1 (en) * 2002-02-27 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
US7300670B2 (en) * 2002-04-03 2007-11-27 Unilab Pharmatech, Ltd. Oral suspension formulation
US20030232097A1 (en) * 2002-06-17 2003-12-18 Strides Inc. Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen
CA2608930A1 (fr) * 2005-06-14 2006-12-28 Baxter International Inc. Preparations pharmaceutiques permettant de reduire les interactions entre medicaments
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
KR20080080119A (ko) * 2005-11-15 2008-09-02 백스터 인터내셔널 인코포레이티드 리폭시게나제 억제제의 조성물
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
WO2008007426A1 (fr) * 2006-07-12 2008-01-17 Aska Pharmaceutical Co., Ltd. Agent analgésique
WO2008080047A2 (fr) * 2006-12-23 2008-07-03 Baxter International Inc. Séparation magnétique de particules fines à partir de compositions
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
PH12013500081B1 (en) * 2010-07-12 2017-09-27 Boehringer Ingelheim Int Aqueous composition comprising bromhexine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6418A (en) * 1987-02-06 1989-01-05 Tanabe Seiyaku Co Ltd Suspension of oxolinic acid
JPH01258618A (ja) * 1987-07-08 1989-10-16 American Home Prod Corp 小児用イブプロフェン組成物
JPH02286615A (ja) * 1989-03-28 1990-11-26 American Home Prod Corp 経口投与用イブプロフェン組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5951214A (ja) 1982-09-16 1984-03-24 Taiho Yakuhin Kogyo Kk バイオアベイラビリテイの高い薬剤の製造方法
NZ234143A (en) 1989-06-28 1991-10-25 Mcneil Ppc Inc Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
TW209174B (fr) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
TW272942B (fr) * 1993-02-10 1996-03-21 Takeda Pharm Industry Co Ltd
JPH08333246A (ja) 1995-06-07 1996-12-17 Taisho Pharmaceut Co Ltd イブプロフェン懸濁液剤
JPH08333265A (ja) 1995-06-07 1996-12-17 Taisho Pharmaceut Co Ltd イブプロフェン懸濁液剤
JPH08337524A (ja) 1995-06-15 1996-12-24 Taisho Pharmaceut Co Ltd イブプロフェン懸濁液剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6418A (en) * 1987-02-06 1989-01-05 Tanabe Seiyaku Co Ltd Suspension of oxolinic acid
JPH01258618A (ja) * 1987-07-08 1989-10-16 American Home Prod Corp 小児用イブプロフェン組成物
JPH02286615A (ja) * 1989-03-28 1990-11-26 American Home Prod Corp 経口投与用イブプロフェン組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0896815A4 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005530822A (ja) * 2002-06-17 2005-10-13 ターロ ファーマシューティカルズ ユーエスエイ インコーポレイテッド イブプロフェン懸濁液
JP2009513550A (ja) * 2003-07-16 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 慢性侵害受容性疼痛の治療のためのアンブロキソール
JP2006315956A (ja) * 2005-05-10 2006-11-24 Taisho Pharmaceut Co Ltd 解熱鎮痛用固形製剤
JP2006327993A (ja) * 2005-05-26 2006-12-07 Aska Pharmaceutical Co Ltd 鎮痛薬
JP2009242383A (ja) * 2008-03-10 2009-10-22 Daiichi Sankyo Healthcare Co Ltd イブプロフェン含有安定化内服液
JP2012525359A (ja) * 2009-04-27 2012-10-22 ラボラトリオ デ アプリカシオネス ファルマコディナミカス，エセ．アー． イブプロフェンリシナートの経口投与用の懸濁液

Also Published As

Publication number Publication date
EP0896815A1 (fr) 1999-02-17
AU717764B2 (en) 2000-03-30
EP0896815A4 (fr) 2000-02-09
KR20000010696A (ko) 2000-02-25
CA2253260A1 (fr) 1997-11-13
US6231890B1 (en) 2001-05-15
AU2650397A (en) 1997-11-26
CN1220598A (zh) 1999-06-23

Similar Documents

Publication Publication Date Title
WO1997041832A1 (fr) Suspension de medicament acide difficilement soluble dans l'eau
EP1318788B1 (fr) Compositions posologiques solides nanoparticulaires
US6656505B2 (en) Method for forming an aqueous flocculated suspension
TWI547281B (zh) 用於治療口腔疾病之包含瑞巴派特之醫藥組成物
TW201043264A (en) Reduction of flake-like aggregation in nanoparticulate active agent compositions
AU777413B2 (en) Ziprasidone suspension
JP2019196367A (ja) アプレピタント経口液体製剤
TW201014615A (en) A complex organic compound powder for medicine, the preparation method thereof and the suspension
US11701352B2 (en) Process for preparing aripiprazole oral soluble film
WO2008048018A1 (fr) Suspension d'un matériau à base de megestrol pharmaceutiquement stable
JPWO1997041832A1 (ja) 水難溶性酸性薬物の懸濁液剤
EP4565243A1 (fr) Formulations orales d'acétate d'abiratérone et leur procédé de fabrication
CN105327359A (zh) 一种用于治疗口腔疾病的药物及其制备方法
JP6578828B2 (ja) 医薬品組成物
JP2013056845A (ja) 固体内服医薬組成物及びその製造方法
HK1019709A (en) Suspension of sparingly water-soluble acidic drug

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97195169.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09171631

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2253260

Country of ref document: CA

Ref document number: 2253260

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019980708774

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1997918348

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997918348

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019980708774

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997918348

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019980708774

Country of ref document: KR